Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topiramate oral - Eton Pharmaceuticals

Next Previous
Drug Profile

Topiramate oral - Eton Pharmaceuticals

Alternative Names: EPRONTIA; ET-101 - Eton Pharmaceuticals

Latest Information Update: 28 Apr 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eton Pharmaceuticals
  • Class Antiepileptic drugs; Antimigraines; Dioxolanes; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Pyrans; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Lennox-Gastaut syndrome; Migraine; Tonic-clonic epilepsy
  • No development reported Epilepsy

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for clinical-Phase-Unknown development in Epilepsy(Adjunctive treatment, In adolescents, In children, In infants) in USA (PO, Liquid)
  • 28 Apr 2022 No recent reports of development identified for clinical-Phase-Unknown development in Epilepsy(In adolescents, In children, In infants) in USA (PO, Liquid)
  • 28 Jan 2022 Launched for Lennox-Gastaut syndrome (Adjunctive treatment, In adolescents, In children, In adults) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top